Pipeline

Powered by Molecule Pro

Program
Modality
Indication
Discovery
Optimization
IND-Enabling
Clinical
Partner
Wholly Owned
MDR-001
Small Molecule GLP-1RA
Obesity, Type 2 Diabetes
Potential Best-in-Class
MRANK-023
Undisclosed
Undisclosed
MRANK-002
Undisclosed
Undisclosed
MRANK-603
Undisclosed
Undisclosed
Out-Licensed
Co-developed
3 Programs
Undisclosed
Undisclosed
Public Traded Biotech
8 Programs
Undisclosed
Undisclosed
Design as a Service
EMRANK-016
Allosteric Inhibitor
Oncology
PCC delivered
Public Traded Biotech
EMRANK-189
Undisclosed
Undisclosed
Lead delivered
Public Traded Biotech